PLETAL (Otsuka America Pharmaceutical, Inc.)
Welcome to the PulseAid listing for the PLETAL drug offered from Otsuka America Pharmaceutical, Inc.. This Phosphodiesterase 3 Inhibitor [EPC],Phosphodiesterase 3 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Otsuka America Pharmaceutical, Inc. |
NON-PROPRIETARY NAME: | cilostazol |
SUBSTANCE NAME: | CILOSTAZOL |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Phosphodiesterase 3 Inhibitor [EPC],Phosphodiesterase 3 Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 1999-01-15 |
END MARKETING DATE: | 2017-11-30 |
PLETAL HUMAN PRESCRIPTION DRUG Details:
Item Description | PLETAL from Otsuka America Pharmaceutical, Inc. |
LABELER NAME: | Otsuka America Pharmaceutical, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 50(mg/1) |
START MARKETING DATE: | 1999-01-15 |
END MARKETING DATE: | 2017-11-30 |
PRODUCT ID: | 59148-003_bb0e7b3b-966b-4d6a-a0d6-6eceeb0fb6a2 |
PRODUCT NDC: | 59148-003 |
APPLICATION NUMBER: | NDA020863 |
Other CILOSTAZOL Pharmaceutical Manufacturers / Labelers: